This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bourgault, A.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bourgault, A.-M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2006, p. 3473-3475, Vol. 50, No. 10
0066-4804/06/$08.00+0     doi:10.1128/AAC.00479-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

In Vitro Susceptibility of Clostridium difficile Clinical Isolates from a Multi-Institutional Outbreak in Southern Québec, Canada

Anne-Marie Bourgault,1 François Lamothe,1* Vivian G. Loo,2 Louise Poirier,3 and the CDAD-CSI Study Group

Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada,1 McGill University Health Centre, Montréal, QC, Canada,2 Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada3

Received 18 April 2006/ Returned for modification 23 May 2006/ Accepted 18 July 2006

Clostridium difficile isolates from a 2004 outbreak in Québec, Canada, were all found to be susceptible to metronidazole, vancomycin, rifampin, and meropenem but resistant to bacitracin, cefotaxime, ciprofloxacin, and levofloxacin, and most (>80%) were resistant to ceftriaxone, clarithromycin, gatifloxacin, and moxifloxacin. The predominant NAP1 isolates were susceptible to clindamycin, while the NAP2 isolates were resistant.

* Corresponding author. Mailing address: Dept. de Microbiologie Médicale et Infectiologie, Hôpital St-Luc, Centre Hospitalier de l'Université de Montréal, 1058 St-Denis, Montréal, QC, Canada H2X 3J4. Phone: (514) 890-8000, ext. 36210. Fax: (514) 412-7412. E-mail: francois.lamothe.CHUM{at}ssss.gouv.qc.ca.

Antimicrobial Agents and Chemotherapy, October 2006, p. 3473-3475, Vol. 50, No. 10
0066-4804/06/$08.00+0     doi:10.1128/AAC.00479-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Critchley, I. A., Green, L. S., Young, C. L., Bullard, J. M., Evans, R. J., Price, M., Jarvis, T. C., Guiles, J. W., Janjic, N., Ochsner, U. A. (2009). Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections. J Antimicrob Chemother 63: 954-963 [Abstract] [Full Text]  
  • Karlowsky, J. A., Laing, N. M., Zhanel, G. G. (2008). In Vitro Activity of OPT-80 Tested against Clinical Isolates of Toxin-Producing Clostridium difficile. Antimicrob. Agents Chemother. 52: 4163-4165 [Abstract] [Full Text]  
  • Wargo, K. A., Wright, B. M., Gupta, R. (2008). The Utility of Fluoroquinolones in the Critically Ill. Journal of Pharmacy Practice 21: 346-355 [Abstract]  
  • Garey, K. W, Salazar, M., Shah, D., Rodrigue, R., DuPont, H. L (2008). Rifamycin Antibiotics for Treatment of Clostridium difficile-Associated Diarrhea. The Annals of Pharmacotherapy 42: 827-835 [Abstract] [Full Text]  
  • Akerlund, T., Persson, I., Unemo, M., Noren, T., Svenungsson, B., Wullt, M., Burman, L. G. (2008). Increased Sporulation Rate of Epidemic Clostridium difficile Type 027/NAP1. J. Clin. Microbiol. 46: 1530-1533 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»